

Herbert L Bonkovsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1142888/publications.pdf>

Version: 2024-02-01

252
papers

21,584
citations

7551

77
h-index

10708

138
g-index

257
all docs

257
docs citations

257
times ranked

18320
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1416-e1425. | 2.4 | 13 |
| 2 | Acute Hepatic Porphyrrias: “Purple Flags” Clinical Features That Should Prompt Specific Diagnostic Testing. <i>American Journal of the Medical Sciences</i> , 2022, 363, 1-10. | 0.4 | 7 |
| 3 | Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. <i>Liver International</i> , 2022, 42, 161-172. | 1.9 | 41 |
| 4 | Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries. <i>Liver International</i> , 2022, 42, 1323-1329. | 1.9 | 7 |
| 5 | Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. <i>Journal of Hepatology</i> , 2022, 76, 832-840. | 1.8 | 16 |
| 6 | Assessment of porphyrogenicity of drugs and chemicals in selected hepatic cell culture models through a fluorescence-based screening assay. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00951. | 1.1 | 4 |
| 7 | Hepatocellular Carcinoma in Acute Hepatic Porphyrrias: Results from the Longitudinal Study of the U.S. Porphyrrias Consortium. <i>Hepatology</i> , 2021, 73, 1736-1746. | 3.6 | 32 |
| 8 | Givosiran, a novel treatment for acute hepatic porphyrias. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 9-18. | 0.4 | 12 |
| 9 | Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria. <i>Genetics in Medicine</i> , 2021, 23, 140-148. | 1.1 | 17 |
| 10 | Porphyric neuropathy. <i>Muscle and Nerve</i> , 2021, 64, 140-152. | 1.0 | 16 |
| 11 | Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians. <i>American Journal of the Medical Sciences</i> , 2021, 362, 113-121. | 0.4 | 24 |
| 12 | Geographic prevalence variation and phenotype penetrance in porphyria: insights from a Chinese population database. <i>Blood Advances</i> , 2021, 5, 12-15. | 2.5 | 3 |
| 13 | Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria. <i>Genetics in Medicine</i> , 2020, 22, 590-597. | 1.1 | 8 |
| 14 | EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. <i>Hepatology</i> , 2020, 71, 1546-1558. | 3.6 | 103 |
| 15 | Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514. | 3.0 | 37 |
| 16 | Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP). <i>Journal of Medical Economics</i> , 2020, 23, 1441-1449. | 1.0 | 8 |
| 17 | Editorial: hepatitis C and porphyria cutanea tarda in 2020. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1432-1434. | 1.9 | 0 |
| 18 | Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. <i>New England Journal of Medicine</i> , 2020, 382, 2289-2301. | 13.9 | 350 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. <i>Toxicology Reports</i> , 2020, 7, 386-402. | 1.6 | 108 |
| 20 | Erythropoietic Protoporphyrin: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist. <i>Blood</i> , 2020, 136, 51-51. | 0.6 | 8 |
| 21 | Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver Injury. <i>Hepatology Communications</i> , 2019, 3, 1032-1035. | 2.0 | 7 |
| 22 | The Role of Traditional Chinese Medicines (TCM) and Other Complementary and Alternative Medicines (CAM) in the Management of Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2019, 18, 316-321. | 0.4 | 3 |
| 23 | Porphyria-Induced Protein Oxidation and Aggregation as a Mechanism of Porphyria-Associated Cell Injury. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 535-548. | 2.3 | 44 |
| 24 | A Low Iron Diet Protects from Steatohepatitis in a Mouse Model. <i>Nutrients</i> , 2019, 11, 2172. | 1.7 | 7 |
| 25 | Pilot study of mitochondrial bioenergetics in subjects with acute porphyrias. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 228-235. | 0.5 | 20 |
| 26 | Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 α -type voltage-gated calcium channels and Ca^{2+} influx. <i>EBioMedicine</i> , 2019, 44, 209-224. | 2.7 | 31 |
| 27 | International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. <i>Genetics in Medicine</i> , 2019, 21, 2605-2613. | 1.1 | 16 |
| 28 | Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs). <i>Molecular Genetics and Metabolism</i> , 2019, 128, 213-218. | 0.5 | 63 |
| 29 | Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1195-1204. | 1.9 | 43 |
| 30 | Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. <i>New England Journal of Medicine</i> , 2019, 380, 549-558. | 13.9 | 194 |
| 31 | Acute Hepatic Porphyrias: Review and Recent Progress. <i>Hepatology Communications</i> , 2019, 3, 193-206. | 2.0 | 91 |
| 32 | Benefits of prophylactic heme therapy in severe acute intermittent porphyria. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 19, 100450. | 0.4 | 24 |
| 33 | Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 242-253. | 0.5 | 31 |
| 34 | Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 376-381. | 0.5 | 16 |
| 35 | Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. <i>Hepatology</i> , 2019, 69, 760-773. | 3.6 | 166 |
| 36 | Baseline Hepatic Levels of miR-29b and Claudin are Respectively Associated with the Stage of Fibrosis and HCV RNA in Hepatitis C. , 2019, 1, . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Reply. <i>Hepatology</i> , 2018, 67, 803-804. | 3.6 | 0 |
| 38 | Cytokine profiles in acute liver injury—Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group. <i>PLoS ONE</i> , 2018, 13, e0206389. | 1.1 | 29 |
| 39 | miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. <i>PLoS ONE</i> , 2018, 13, e0200847. | 1.1 | 44 |
| 40 | Peripheral Neuropathy and the Ceruloplasmin Gene. <i>Annals of Internal Medicine</i> , 2018, 168, 894. | 2.0 | 4 |
| 41 | BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial—mesenchymal transition via upregulating ID2. <i>Cancer Letters</i> , 2017, 390, 67-76. | 3.2 | 36 |
| 42 | Associations of gender and a proxy of female menopausal status with histological features of drug—induced liver injury. <i>Liver International</i> , 2017, 37, 1723-1730. | 1.9 | 18 |
| 43 | Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. <i>Journal of Immunotoxicology</i> , 2017, 14, 31-38. | 0.9 | 32 |
| 44 | Acute hepatic porphyrias: Recommendations for evaluation and long—term management. <i>Hepatology</i> , 2017, 66, 1314-1322. | 3.6 | 122 |
| 45 | Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyrinemia and X-linked Protoporphyrinemia. <i>JAMA Dermatology</i> , 2017, 153, 789. | 2.0 | 70 |
| 46 | Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. <i>Hepatology</i> , 2017, 65, 1267-1277. | 3.6 | 105 |
| 47 | BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma. <i>Cancer Letters</i> , 2017, 411, 117-129. | 3.2 | 58 |
| 48 | Porphyria. <i>New England Journal of Medicine</i> , 2017, 377, 862-872. | 13.9 | 272 |
| 49 | Porphyria Cutanea Tarda: Profile of 189 Patients from the Porphyrias Consortium in the United States. <i>Gastroenterology</i> , 2017, 152, S1156. | 0.6 | 1 |
| 50 | Porphyria. <i>New England Journal of Medicine</i> , 2017, 377, 2100-2101. | 13.9 | 13 |
| 51 | Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. <i>Liver International</i> , 2017, 37, 757-764. | 1.9 | 49 |
| 52 | Advances in the management of erythropoietic protoporphyria — role of afamelanotide. <i>The Application of Clinical Genetics</i> , 2016, Volume 9, 179-189. | 1.4 | 23 |
| 53 | Amoxicillin—Clavulanate-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2406-2416. | 1.1 | 92 |
| 54 | Hepatotoxicity Associated with the Use of Anti-TNF— Agents. <i>Drug Safety</i> , 2016, 39, 199-208. | 1.4 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. <i>Blood</i> , 2016, 128, 2318-2318. | 0.6 | 3 |
| 56 | Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. <i>World Journal of Gastroenterology</i> , 2016, 22, 6742. | 1.4 | 74 |
| 57 | Indications for liver transplant and AASLD guidelines. <i>Hepatology</i> , 2015, 61, 408-408. | 3.6 | 8 |
| 58 | Homeostasis of iron and hepcidin in erythropoietic protoporphyria. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1032-1041. | 1.7 | 18 |
| 59 | Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of Protoporphyrins. <i>Clinical Chemistry</i> , 2015, 61, 1453-1456. | 1.5 | 29 |
| 60 | Herbal Dietary Supplement Associated Hepatotoxicity: An Upcoming Workshop and Need for Research. <i>Gastroenterology</i> , 2015, 148, 480-482. | 0.6 | 14 |
| 61 | Acute Porphyrias. <i>Journal of Emergency Medicine</i> , 2015, 49, 305-312. | 0.3 | 47 |
| 62 | Afamelanotide for Erythropoietic Protoporphyria. <i>New England Journal of Medicine</i> , 2015, 373, 48-59. | 13.9 | 206 |
| 63 | Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. <i>Journal of Hepatology</i> , 2015, 63, 1103-1110. | 1.8 | 61 |
| 64 | On Stress and the Liver: A Chicken and Egg Conundrum. <i>Gastroenterology</i> , 2015, 148, 894-897. | 0.6 | 5 |
| 65 | Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. <i>Gastroenterology</i> , 2015, 148, 1340-1352.e7. | 0.6 | 646 |
| 66 | Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy. <i>American Journal of Cardiology</i> , 2015, 116, 1752-1755. | 0.7 | 7 |
| 67 | Leukocyte expression of heme oxygenase-1 [hmx1] varies inversely with severity of tricuspid regurgitation in acute pulmonary embolism. <i>Thrombosis Research</i> , 2015, 136, 769-774. | 0.8 | 6 |
| 68 | Recent insights into the biological functions of liver fatty acid binding protein 1. <i>Journal of Lipid Research</i> , 2015, 56, 2238-2247. | 2.0 | 164 |
| 69 | Herbal Products and the Liver: A Review of Adverse Effects and Mechanisms. <i>Gastroenterology</i> , 2015, 148, 517-532.e3. | 0.6 | 97 |
| 70 | miR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA. <i>Liver International</i> , 2015, 35, 1315-1323. | 1.9 | 26 |
| 71 | Risk factors for severe or fatal drug-induced liver injury from amoxicillin-clavulanic acid. <i>Hepatology Research</i> , 2015, 45, 676-682. | 1.8 | 7 |
| 72 | Drug-Induced Liver Injury with Autoimmune Features. <i>Seminars in Liver Disease</i> , 2014, 34, 194-204. | 1.8 | 109 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. <i>Hepatology</i> , 2014, 59, 661-670. | 3.6 | 322 |
| 74 | Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. <i>Hepatology</i> , 2014, 60, 679-686. | 3.6 | 200 |
| 75 | Novel role of nuclear receptor rev-erb α in hepatic stellate cell activation: Potential therapeutic target for liver injury. <i>Hepatology</i> , 2014, 59, 2383-2396. | 3.6 | 43 |
| 76 | Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. <i>Hepatology</i> , 2014, 60, 1399-1408. | 3.6 | 326 |
| 77 | Acute Porphyrías in the USA: Features of 108 Subjects from Porphyrías Consortium. <i>American Journal of Medicine</i> , 2014, 127, 1233-1241. | 0.6 | 185 |
| 78 | Hepatotoxicity of Anti-TNF Agents. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1070-1071. | 1.1 | 5 |
| 79 | ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. <i>American Journal of Gastroenterology</i> , 2014, 109, 950-966. | 0.2 | 631 |
| 80 | Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrías. <i>Metabolites</i> , 2014, 4, 977-1006. | 1.3 | 92 |
| 81 | Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. <i>World Journal of Gastroenterology</i> , 2014, 20, 14142. | 1.4 | 19 |
| 82 | Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1766-1775. | 1.1 | 26 |
| 83 | Circadian rhythms in acute intermittent porphyria – a pilot study. <i>European Journal of Clinical Investigation</i> , 2013, 43, 727-739. | 1.7 | 10 |
| 84 | Chronic Hepatitis E with Neurologic Manifestations and Rapid Progression of Liver Fibrosis in a Liver Transplant Recipient. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2413-2416. | 1.1 | 25 |
| 85 | Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer. <i>Proteomics</i> , 2013, 13, 3554-3562. | 1.3 | 5 |
| 86 | Cytoskeletal Proteins. <i>International Review of Cell and Molecular Biology</i> , 2013, 302, 279-319. | 1.6 | 3 |
| 87 | A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. <i>Nature Genetics</i> , 2013, 45, 164-171. | 9.4 | 843 |
| 88 | Risk factors for porphyria cutanea tarda – the iron/HFE connection. <i>Liver International</i> , 2013, 33, 162-162. | 1.9 | 0 |
| 89 | Catechins in Dietary Supplements and Hepatotoxicity. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2682-2690. | 1.1 | 71 |
| 90 | Porphyrin and Heme Metabolism and the Porphyrías. , 2013, 3, 365-401. | | 134 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Liver Injury From Tumor Necrosis Factor- α Antagonists: Analysis of Thirty-four Cases. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 558-564.e3. | 2.4 | 187 |
| 92 | Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 7836. | 1.4 | 34 |
| 93 | Profiles of Serum Cytokines in Acute Drug-Induced Liver Injury and Their Prognostic Significance. <i>PLoS ONE</i> , 2013, 8, e81974. | 1.1 | 71 |
| 94 | Heme status affects human hepatic messenger RNA and microRNA expression. <i>World Journal of Gastroenterology</i> , 2013, 19, 1593. | 1.4 | 4 |
| 95 | <scp>YKL</scp>â€40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. <i>Liver International</i> , 2012, 32, 665-674. | 1.9 | 21 |
| 96 | Hepatitis <scp>C</scp>, porphyria cutanea tarda and liver iron: an update. <i>Liver International</i> , 2012, 32, 880-893. | 1.9 | 96 |
| 97 | The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2012, 1819, 1113-1122. | 0.9 | 89 |
| 98 | Drug-Induced Liver Injury. , 2012, , 417-461. | | 7 |
| 99 | Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. <i>Hepatology</i> , 2012, 56, 300-310. | 3.6 | 177 |
| 100 | Chinese medicine for treatment of chronic hepatitis B. <i>Chinese Journal of Integrative Medicine</i> , 2012, 18, 253-255. | 0.7 | 17 |
| 101 | DNA methylation patterns in alcoholics and family controls. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 138. | 0.8 | 15 |
| 102 | Abstract 709: Angiogenic switch: novel therapeutic target for pancreatic cancer. , 2012, , . | | 0 |
| 103 | Lon Peptidase 1 (LONP1)-dependent Breakdown of Mitochondrial 5-Aminolevulinic Acid Synthase Protein by Heme in Human Liver Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 26424-26430. | 1.6 | 111 |
| 104 | Subcellular Tissue Proteomics of Hepatocellular Carcinoma for Molecular Signature Discovery. <i>Journal of Proteome Research</i> , 2011, 10, 5070-5083. | 1.8 | 36 |
| 105 | Malloryâ€™Denk Bodies Are Associated With Outcomes and Histologic Features in Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 902-909.e1. | 2.4 | 22 |
| 106 | Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 840-849.e1. | 0.6 | 178 |
| 107 | Iron Levels in Hepatocytes and Portal Tract Cells Predict Progression and Outcomes of Patients With Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 1490-1500.e3. | 0.6 | 64 |
| 108 | microRNAs: Fad or future of liver disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 2536. | 1.4 | 80 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Intrahepatic Stainable Iron and Cardiac Dysfunction Pre- and Post- Orthotopic Liver Transplantation. <i>Gastroenterology</i> , 2011, 140, S-965. | 0.6 | 0 |
| 110 | Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method. <i>Clinica Chimica Acta</i> , 2011, 412, 2241-2247. | 0.5 | 17 |
| 111 | Respiration and ROS production in brain and spinal cord mitochondria of transgenic rats with mutant G93a Cu/Zn-superoxide dismutase gene. <i>Neurobiology of Disease</i> , 2011, 44, 53-62. | 2.1 | 30 |
| 112 | Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. <i>Hepatology</i> , 2011, 53, 1100-1108. | 3.6 | 55 |
| 113 | A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2011, 54, 396-405. | 3.6 | 142 |
| 114 | Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. <i>Journal of Proteomics</i> , 2011, 74, 79-88. | 1.2 | 28 |
| 115 | Metabolic and functional differences between brain and spinal cord mitochondria underlie different predisposition to pathology. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2011, 300, R844-R854. | 0.9 | 52 |
| 116 | Neonatal Androgenization Exacerbates Alcohol-Induced Liver Injury in Adult Rats, an Effect Abrogated by Estrogen. <i>PLoS ONE</i> , 2011, 6, e29463. | 1.1 | 10 |
| 117 | Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 884-893. | 0.2 | 16 |
| 118 | An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C. <i>PLoS ONE</i> , 2011, 6, e20904. | 1.1 | 25 |
| 119 | Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes. <i>PLoS ONE</i> , 2011, 6, e20922. | 1.1 | 16 |
| 120 | Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. <i>World Journal of Gastroenterology</i> , 2011, 17, 1694. | 1.4 | 18 |
| 121 | Iron and Hepatitis C. <i>Current Hepatitis Reports</i> , 2010, 9, 169-177. | 0.3 | 6 |
| 122 | Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2010, 51, 585-594. | 3.6 | 155 |
| 123 | Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: An analytical review. <i>Hepatology</i> , 2010, 51, 690-698. | 3.6 | 96 |
| 124 | MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. <i>Hepatology</i> , 2010, 51, 1494-1504. | 3.6 | 176 |
| 125 | Genetic variations in heme oxygenase-1 and chronic hepatitis. <i>Hepatology</i> , 2010, 52, 400-401. | 3.6 | 12 |
| 126 | Outcome of sustained virological responders with histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 833-844. | 3.6 | 428 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. <i>Hepatology</i> , 2010, 52, 1671-1779. | 3.6 | 103 |
| 128 | Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus. <i>Liver International</i> , 2010, 30, 1490-1504. | 1.9 | 31 |
| 129 | Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. <i>Gut</i> , 2010, 59, 1401-1409. | 6.1 | 92 |
| 130 | Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 136-146. | 0.6 | 82 |
| 131 | Des-Î ³ -Carboxy Prothrombin and Î±-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 138, 493-502. | 0.6 | 524 |
| 132 | Zinc Mesoporphyrin Induces Rapid Proteasomal Degradation of Hepatitis C Nonstructural 5A Protein in Human Hepatoma Cells. <i>Gastroenterology</i> , 2010, 138, 1909-1919.e3. | 0.6 | 32 |
| 133 | Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 877-883. | 2.4 | 385 |
| 134 | Structural analysis of heme proteins: Implication for design and prediction. , 2010, , . | | 2 |
| 135 | The Neuromediator Glutamate, through Specific Substrate Interactions, Enhances Mitochondrial ATP Production and Reactive Oxygen Species Generation in Nonsynaptic Brain Mitochondria. <i>Journal of Biological Chemistry</i> , 2009, 284, 14448-14456. | 1.6 | 62 |
| 136 | Drug-Induced Liver Injury Associated with Statins. <i>Seminars in Liver Disease</i> , 2009, 29, 412-422. | 1.8 | 132 |
| 137 | Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. <i>Hepatology</i> , 2009, 49, 1828-1837. | 3.6 | 51 |
| 138 | Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2009, 49, 1847-1858. | 3.6 | 75 |
| 139 | Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 1360-1369. | 3.6 | 153 |
| 140 | Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. <i>Hepatology</i> , 2009, 50, 1719-1726. | 3.6 | 20 |
| 141 | Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. <i>Hepatology</i> , 2009, 50, 1738-1749. | 3.6 | 60 |
| 142 | Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. <i>Liver International</i> , 2009, 29, 366-373. | 1.9 | 28 |
| 143 | CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. <i>Journal of Clinical Virology</i> , 2009, 46, 259-264. | 1.6 | 24 |
| 144 | Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. <i>Gastroenterology</i> , 2009, 136, 138-148. | 0.6 | 570 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. <i>Gastroenterology</i> , 2009, 137, 549-557. | 0.6 | 125 |
| 146 | Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. <i>Gastroenterology</i> , 2009, 137, 1986-1994. | 0.6 | 31 |
| 147 | Drug-Induced Liver Injury Network (DILIN) Prospective Study. <i>Drug Safety</i> , 2009, 32, 55-68. | 1.4 | 416 |
| 148 | Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 219-226. | 2.4 | 42 |
| 149 | Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. <i>World Journal of Gastroenterology</i> , 2009, 15, 4499. | 1.4 | 36 |
| 150 | Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. <i>Hepatology</i> , 2008, 47, 605-612. | 3.6 | 114 |
| 151 | Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. <i>Molecular and Cellular Biochemistry</i> , 2008, 319, 153-161. | 1.4 | 33 |
| 152 | Phlebotomy Improves Therapeutic Response to Interferon in Patients with Chronic Hepatitis C: A Meta-Analysis of Six Prospective Randomized Controlled Trials. <i>Digestive Diseases and Sciences</i> , 2008, 53, 815-822. | 1.1 | 58 |
| 153 | Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. <i>Hepatology</i> , 2008, 47, 789-798. | 3.6 | 155 |
| 154 | Tissue-specific expression of ALA synthase and heme oxygenase and their expression in livers of rats chronically exposed to ethanol. <i>FEBS Letters</i> , 2008, 582, 1829-1834. | 1.3 | 7 |
| 155 | Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States. <i>Gastroenterology</i> , 2008, 135, 1924-1934.e4. | 0.6 | 748 |
| 156 | DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. <i>Journal of Hepatology</i> , 2008, 49, 548-556. | 1.8 | 43 |
| 157 | Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor bach1 and up-regulates HO-1. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2008, 1779, 195-203. | 0.9 | 23 |
| 158 | Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 234-241. | 2.4 | 26 |
| 159 | Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration. <i>American Journal of Gastroenterology</i> , 2008, 103, 2757-2765. | 0.2 | 41 |
| 160 | Hereditary Hemochromatosis: Time for Targeted Screening. <i>Annals of Internal Medicine</i> , 2008, 149, 270. | 2.0 | 50 |
| 161 | Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate. <i>Circulation Research</i> , 2008, 102, 669-676. | 2.0 | 420 |
| 162 | Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. <i>New England Journal of Medicine</i> , 2008, 359, 2429-2441. | 13.9 | 445 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Case 20-2008. <i>New England Journal of Medicine</i> , 2008, 358, 2813-2825. | 13.9 | 37 |
| 164 | Regarding "Cobalt protoporphyrin as a potential therapeutic agent". <i>FASEB Journal</i> , 2007, 21, 2640-2640. | 0.2 | 1 |
| 165 | Genetic Aspects of Porphyria Cutanea Tarda. <i>Seminars in Liver Disease</i> , 2007, 27, 099-108. | 1.8 | 42 |
| 166 | Marked Hyperbilirubinemia Associated With the Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism in a Boy With Autoimmune Hemolytic Anemia. <i>Pediatrics</i> , 2007, 119, e764-e767. | 1.0 | 15 |
| 167 | Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. <i>Journal of Hepatology</i> , 2007, 46, 420-431. | 1.8 | 125 |
| 168 | Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection. <i>Hepatology Research</i> , 2007, 37, 172-178. | 1.8 | 25 |
| 169 | Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 245-254. | 2.4 | 46 |
| 170 | Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 103-112. | 0.6 | 200 |
| 171 | Reciprocal Effects of Micro-RNA-122 on Expression of Heme Oxygenase-1 and Hepatitis C Virus Genes in Human Hepatocytes. <i>Gastroenterology</i> , 2007, 133, 1166-1174. | 0.6 | 157 |
| 172 | Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2006, 131, 1440-1451. | 0.6 | 83 |
| 173 | HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. <i>Journal of Hepatology</i> , 2006, 45, 5-12. | 1.8 | 46 |
| 174 | Hepatotoxicity due to extracts of Chinese green tea (<i>Camellia sinensis</i>): A growing concern. <i>Journal of Hepatology</i> , 2006, 45, 334-335. | 1.8 | 52 |
| 175 | Reconstitution of Hematin for Intravenous Infusion. <i>Annals of Internal Medicine</i> , 2006, 144, 537. | 2.0 | 37 |
| 176 | Autoimmune Hepatitis Triggered by Statins. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 757-761. | 1.1 | 128 |
| 177 | Hepatotoxicity Associated with Supplements Containing Chinese Green Tea (<i>Camellia sinensis</i>). <i>Annals of Internal Medicine</i> , 2006, 144, 68. | 2.0 | 199 |
| 178 | HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. <i>Hepatology</i> , 2006, 44, 360-367. | 3.6 | 46 |
| 179 | Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. <i>Hepatology</i> , 2006, 44, 1675-1684. | 3.6 | 145 |
| 180 | Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. <i>FASEB Journal</i> , 2006, 20, 2651-2653. | 0.2 | 142 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. <i>Biochemical Journal</i> , 2005, 392, 173-180. | 1.7 | 32 |
| 182 | Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. <i>Hepatology</i> , 2005, 41, 617-625. | 3.6 | 32 |
| 183 | Liver transplantation for erythropoietic protoporphyria liver disease. <i>Liver Transplantation</i> , 2005, 11, 1590-1596. | 1.3 | 136 |
| 184 | Iron in Nonhemochromatotic Liver Disorders. <i>Seminars in Liver Disease</i> , 2005, 25, 461-472. | 1.8 | 116 |
| 185 | Fatal air and bile embolism after percutaneous liver biopsy and ERCP. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 153-157. | 0.5 | 38 |
| 186 | No Role of the α^{2518} Promoter Polymorphism of Monocyte Chemotactic Protein-1 in Chronic Hepatitis C. <i>Gastroenterology</i> , 2005, 129, 1361-1362. | 0.6 | 9 |
| 187 | Recommendations for the Diagnosis and Treatment of the Acute Porphyrrias. <i>Annals of Internal Medicine</i> , 2005, 142, 439. | 2.0 | 485 |
| 188 | Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis. <i>Virology Journal</i> , 2005, 2, 41. | 1.4 | 9 |
| 189 | Role of Bach-1 in Regulation of Heme Oxygenase-1 in Human Liver Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 51769-51774. | 1.6 | 62 |
| 190 | Identification of key elements that are responsible for heme-mediated induction of the avian heme oxygenase-1 gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2004, 1679, 87-94. | 2.4 | 18 |
| 191 | Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3 \hat{t} . <i>Gastroenterology</i> , 2004, 126, 1015-1023. | 0.6 | 436 |
| 192 | Iron as a co-morbid factor in nonhemochromatotic liver disease. <i>Alcohol</i> , 2003, 30, 137-144. | 0.8 | 93 |
| 193 | Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. <i>British Journal of Pharmacology</i> , 2003, 139, 634-640. | 2.7 | 44 |
| 194 | Relationship between nonalcoholic steatohepatitis and heterozygosity for the LCHAD (G1528C) mutation. <i>Gastroenterology</i> , 2003, 124, A748. | 0.6 | 0 |
| 195 | Optimal Management of Nonalcoholic Fatty Liver/Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 193-195. | 1.1 | 0 |
| 196 | Iron as a comorbid factor in chronic viral hepatitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 1-4. | 0.2 | 129 |
| 197 | Mapping of the Chick Heme Oxygenase-1 Proximal Promoter for Responsiveness to Metalloporphyrins. <i>Archives of Biochemistry and Biophysics</i> , 2002, 399, 159-166. | 1.4 | 29 |
| 198 | Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 37, 848-854. | 1.8 | 108 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1632-1637. | 1.1 | 62 |
| 200 | BENEFITS OF CHRONIC PLASMAPHERESIS AND INTRAVENOUS HEME-ALBUMIN IN ERYTHROPOIETIC PROTOPORPHYRIA AFTER ORTHOTOPIC LIVER TRANSPLANTATION ¹² . <i>Transplantation</i> , 2002, 73, 469-472. | 0.5 | 48 |
| 201 | Urea and hypertonicity increase expression of heme oxygenase-1 in murine renal medullary cells. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, F983-F991. | 1.3 | 21 |
| 202 | Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. <i>Hepatology</i> , 2000, 31, 730-736. | 3.6 | 154 |
| 203 | Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. <i>Hepatology</i> , 2000, 32, 135-138. | 3.6 | 162 |
| 204 | Ubiquitin as a Marker of Cell Injury in Nonalcoholic Steatohepatitis. <i>American Journal of Clinical Pathology</i> , 2000, 114, 860-866. | 0.4 | 44 |
| 205 | Management of recurrent hepatitis C after liver transplantation: a concise review. <i>American Journal of Gastroenterology</i> , 2000, 95, 2164-2170. | 0.2 | 15 |
| 206 | Induction of the Heme Oxygenase-1 Gene by Metalloporphyrins. <i>Archives of Biochemistry and Biophysics</i> , 2000, 380, 219-227. | 1.4 | 100 |
| 207 | Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. <i>American Journal of Gastroenterology</i> , 2000, 95, 272-276. | 0.2 | 190 |
| 208 | Design of the halt-C trial (Hepatitis C antiviral long-term treatment to prevent Cirrhosis). <i>Gastroenterology</i> , 2000, 118, A1435. | 0.6 | 3 |
| 209 | Iron, the major HFE gene mutation and chronic hepatitis C. <i>Gastroenterology</i> , 2000, 118, A953. | 0.6 | 1 |
| 210 | Hepatic Iron Concentration: Noninvasive Estimation by Means of MR Imaging Techniques. <i>Radiology</i> , 1999, 212, 227-234. | 3.6 | 144 |
| 211 | IFN-alpha Receptor mRNA Expression in a United States Sample with Predominantly Genotype 1a/1 Chronic Hepatitis C Liver Biopsies Correlates with Response to IFN Therapy. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 1011-1018. | 0.5 | 33 |
| 212 | Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation—Abbreviations: ACE, angiotensin converting enzyme; ALA, 5-aminolevulinic acid; CELCs, chick embryo liver cells; and DES, desferrioxamine. <i>Biochemical Pharmacology</i> , 1999, 58, 887-896. | 2.0 | 23 |
| 213 | Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. <i>Hepatology</i> , 1999, 29, 264-270. | 3.6 | 377 |
| 214 | Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. <i>Hepatology</i> , 1999, 29, 1672-1679. | 3.6 | 107 |
| 215 | Heme biosynthesis in a chicken hepatoma cell line (LMH): comparison with primary chick embryo liver cells (CELC). <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1999, 1472, 658-667. | 1.1 | 16 |
| 216 | Effects of Phenylarsine Oxide on Expression of Heme Oxygenase-1 Reporter Constructs in Transiently Transfected Cultures of Chick Embryo Liver Cells. <i>Archives of Biochemistry and Biophysics</i> , 1999, 372, 224-229. | 1.4 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Heme Oxygenase: Recent Advances in Understanding Its Regulation and Role. Proceedings of the Association of American Physicians, 1999, 111, 438-447. | 2.1 | 281 |
| 218 | THE VALUE OF INTRAVENOUS HEME-ALBUMIN AND PLASMAPHERESIS IN REDUCING POSTOPERATIVE COMPLICATIONS OF ORTHOTOPIC LIVER TRANSPLANTATION FOR ERYTHROPOIETIC PROTOPORPHYRIA1,2. Transplantation, 1999, 67, 922-928. | 0.5 | 42 |
| 219 | Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america. Hepatology, 1998, 27, 1661-1669. | 3.6 | 252 |
| 220 | Interleukin-8 and hIRH (SDF1- α /PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C. Hepatology, 1998, 28, 108-115. | 3.6 | 72 |
| 221 | Porphyrin Loading of Lipofuscin Granules in Inflamed Striated Muscle. American Journal of Pathology, 1998, 153, 703-708. | 1.9 | 7 |
| 222 | Enhanced Phenotypic Expression of Alpha-1-Antitrypsin Deficiency in an MZ Heterozygote With Chronic Hepatitis C. American Journal of Gastroenterology, 1998, 93, 1541-1545. | 0.2 | 22 |
| 223 | Regulation of expression of the human heme oxygenase-1 gene in transfected chick embryo liver cell cultures. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1352, 293-302. | 2.4 | 24 |
| 224 | Hepatic 5-Aminolevulinic Acid Synthase mRNA Stability is Modulated by Inhibitors of Heme Biosynthesis and by Metalloporphyrins. FEBS Journal, 1996, 240, 112-117. | 0.2 | 17 |
| 225 | Iron and Chronic Viral Hepatitis: Emerging Evidence for an Important Interaction. Digestive Diseases, 1995, 13, 223-238. | 0.8 | 33 |
| 226 | Putting the freeze on hepatitis C virus-associated mixed cryoglobulinemia. Hepatology, 1995, 21, 594-597. | 3.6 | 1 |
| 227 | Acetaminophen Hepatotoxicity, Fasting, and Ethanol. JAMA - Journal of the American Medical Association, 1995, 274, 301. | 3.8 | 4 |
| 228 | Nutritional supplementation in chronic liver disease: An analytical review. Hepatology, 1994, 19, 518-533. | 3.6 | 127 |
| 229 | Effects of hemopexin on heme-mediated repression of 5-aminolevulinic acid synthase and induction of heme oxygenase in cultured hepatocytes. Hepatology, 1994, 20, 741-746. | 3.6 | 16 |
| 230 | Effects of mifepristone (RU-486) on heme metabolism and cytochromes P-450 in cultured chick embryo liver cells. Possible implications for acute porphyria. FEBS Journal, 1994, 225, 651-657. | 0.2 | 22 |
| 231 | Colonic mucosal appearance of Tangier disease in a new patient. Gastrointestinal Endoscopy, 1994, 40, 628-630. | 0.5 | 15 |
| 232 | Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: Evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology, 1994, 19, 1141-1148. | 3.6 | 3 |
| 233 | Repression of hepatic δ -aminolevulinic acid synthase by heme and metalloporphyrins: Relationship to inhibition of heme oxygenase. Hepatology, 1993, 18, 119-127. | 3.6 | 33 |
| 234 | Molecular basis for heme-dependent induction of heme oxygenase in primary cultures of chick embryo hepatocytes. Demonstration of acquired refractoriness to heme. FEBS Journal, 1993, 213, 909-917. | 0.2 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Advances in understanding and treating "the little imitator," acute porphyria. <i>Gastroenterology</i> , 1993, 105, 590-594. | 0.6 | 43 |
| 236 | Synergistic induction of δ -aminolevulinatase synthase by glutethimide and iron: relationship to the synergistic induction of heme oxygenase. <i>BBA - Proteins and Proteomics</i> , 1991, 1080, 245-251. | 2.1 | 21 |
| 237 | Activation of the hepatocarcinogen aflatoxin B1 by forms of human hepatic cytochromes P-450: Some do and some don't. <i>Hepatology</i> , 1991, 13, 1003-1005. | 3.6 | 1 |
| 238 | Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. <i>Gastroenterology</i> , 1990, 99, 1079-1091. | 0.6 | 104 |
| 239 | Purification and characterization of heme oxygenase from chick liver. Comparison of the avian and mammalian enzymes. <i>FEBS Journal</i> , 1990, 189, 155-166. | 0.2 | 49 |
| 240 | Prevalence and prediction of osteopenia in chronic liver disease. <i>Hepatology</i> , 1990, 12, 273-280. | 3.6 | 123 |
| 241 | Biochemistry and Pharmacology of S-Adenosyl-L-Methionine and Rationale for its Use in Liver Disease. <i>Drugs</i> , 1990, 40, 98-110. | 4.9 | 59 |
| 242 | Mechanism of iron potentiation of hepatic uroporphyrin: Studies in cultured chick embryo liver cells. <i>Hepatology</i> , 1989, 10, 354-364. | 3.6 | 44 |
| 243 | Heme catabolism in cultured hepatocytes: evidence that heme oxygenase is the predominant pathway and that a proportion of synthesized heme is converted rapidly to biliverdin. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989, 992, 49-58. | 1.1 | 37 |
| 244 | The porphyrias. <i>Disease-a-Month</i> , 1989, 35, 7-54. | 0.4 | 35 |
| 245 | Choline may be an essential nutrient in malnourished patients with cirrhosis. <i>Gastroenterology</i> , 1989, 97, 1514-1520. | 0.6 | 70 |
| 246 | Decreased Hepatic 5-Aminolevulinatase Dehydrase in Experimental Hemochromatosis. <i>Annals of the New York Academy of Sciences</i> , 1988, 526, 365-368. | 1.8 | 2 |
| 247 | Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. <i>Hepatology</i> , 1987, 7, 423-429. | 3.6 | 116 |
| 248 | Hepatic heme synthesis in a new model of experimental hemochromatosis: Studies in rats fed finely divided elemental iron. <i>Hepatology</i> , 1987, 7, 1195-1203. | 3.6 | 31 |
| 249 | Hepatic microsomal function in rats with chronic dietary iron overload. <i>Gastroenterology</i> , 1986, 90, 1844-1853. | 0.6 | 72 |
| 250 | Fatal liver failure in protoporphyria. <i>Gastroenterology</i> , 1986, 90, 191-201. | 0.6 | 62 |
| 251 | High-performance liquid chromatographic separation and quantitation of tetrapyrroles from biological materials. <i>Analytical Biochemistry</i> , 1986, 155, 56-64. | 1.1 | 68 |
| 252 | Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 1827-1845. | 2.0 | 12 |